{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T05:10:50Z","timestamp":1794978650825,"version":"4.9.1"},"reference-count":48,"publisher":"American Association for Cancer Research (AACR)","issue":"3","funder":[{"name":"International Myeloma Society and Paula and Rodger Riney Foundation"},{"name":"International Myeloma Society and Paula and Rodger Riney Foundation"},{"DOI":"10.13039\/501100009379","name":"Interdisziplin\u00e4res Zentrum f\u00fcr Klinische Forschung, Universit\u00e4tsklinikum W\u00fcrzburg","doi-asserted-by":"publisher","award":["ZZ-40"],"award-info":[{"award-number":["ZZ-40"]}],"id":[{"id":"10.13039\/501100009379","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005941","name":"Dietmar Hopp Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005941","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>The significant clinical benefit of bispecific T-cell engagers (TCE) for the treatment of relapsed\/refractory multiple myeloma (RRMM) may be offset by serious toxicities and treatment failure. Risk scores such as the CAR-HEMATOTOX (HTX), Endothelial Activation and Stress Index (EASIX), and modified EASIX (m-EASIX) can identify patients at risk for complications before chimeric antigen receptor (CAR) T-cell therapy, but their utility prior to TCE therapy remains elusive. We analyzed associations with outcomes and toxicities in independent discovery (n = 123) and validation (n = 155) cohorts treated with TCEs. Patients with HTX \u22653 or m-EASIX &amp;gt; median (&amp;gt;0.86) had a significantly increased risk of prolonged hospitalization, antibiotic treatment, and fever during step-up dosing. We also observed associations with cytopenias requiring therapeutic intervention, higher severe infection and intervention densities, as well as inferior response rates and reduced progression-free and overall survival. Our findings highlight the potential of these clinical scores to improve risk stratification before TCE therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Scores such as HTX, EASIX, and m-EASIX have emerged as helpful tools to enable risk stratification before CAR T-cell therapy. In this study, we demonstrate their utility in patients with RRMM receiving TCEs. HTX \u22653 and m-EASIX &amp;gt; median (&amp;gt;0.86) proved to be risk markers for infections, therapeutic interventions, and poor outcomes.<\/jats:p>\n                    <jats:p>See related commentary by Banerjee and Dhodapkar, p. 345<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2643-3230.bcd-25-0062","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T20:46:51Z","timestamp":1771015611000},"page":"479-495","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical Scores to Predict Toxicities and Outcomes in Patients with Multiple Myeloma Undergoing Bispecific T-cell Engager Therapy"],"prefix":"10.1158","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-9682-2601","authenticated-orcid":false,"given":"Jan H.","family":"Frenking","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/038t36y30","id-type":"ROR","asserted-by":"publisher"}],"name":"Heidelberg University 1 Heidelberg Myeloma Center, Department of Medicine V, University Hospital and Medical Faculty Heidelberg, , Heidelberg, Germany."},{"id":[{"id":"https:\/\/ror.org\/04cdgtt98","id-type":"ROR","asserted-by":"publisher"}],"name":"German Cancer Research Center (DKFZ) 2 Clinical Cooperation Unit Molecular Hematology\/Oncology, , Heidelberg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7106-7217","authenticated-orcid":false,"given":"Christine","family":"Riedhammer","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03pvr2g57","id-type":"ROR","asserted-by":"publisher"}],"name":"University Hospital of W\u00fcrzburg 3 Department of Internal Medicine II, , W\u00fcrzburg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1277-310X","authenticated-orcid":false,"given":"Thomas","family":"Hielscher","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04cdgtt98","id-type":"ROR","asserted-by":"publisher"}],"name":"German Cancer Research Center (DKFZ) 4 Division of Biostatistics, , Heidelberg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6494-5105","authenticated-orcid":false,"given":"Christoph","family":"Schaefers","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01zgy1s35","id-type":"ROR","asserted-by":"publisher"}],"name":"University Medical Center Hamburg-Eppendorf 5 Department of Hematology, Oncology and Bone Marrow Transplantation With Section of Pneumology, , Hamburg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9248-588X","authenticated-orcid":false,"given":"Lisa B.","family":"Leypoldt","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01zgy1s35","id-type":"ROR","asserted-by":"publisher"}],"name":"University Medical Center Hamburg-Eppendorf 5 Department of Hematology, Oncology and Bone Marrow Transplantation With Section of Pneumology, , Hamburg, Germany."},{"id":[{"id":"https:\/\/ror.org\/01zgy1s35","id-type":"ROR","asserted-by":"publisher"}],"name":"University Medical Center Hamburg-Eppendorf 6 Mildred Scheel Early Career Center, , Hamburg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0763-3823","authenticated-orcid":false,"given":"Marie","family":"Harzer","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01zgy1s35","id-type":"ROR","asserted-by":"publisher"}],"name":"University Medical Center Hamburg-Eppendorf 5 Department of Hematology, Oncology and Bone Marrow Transplantation With Section of Pneumology, , Hamburg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5312-6743","authenticated-orcid":false,"given":"David","family":"Sedloev","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/038t36y30","id-type":"ROR","asserted-by":"publisher"}],"name":"Heidelberg University 1 Heidelberg Myeloma Center, Department of Medicine V, University Hospital and Medical Faculty Heidelberg, , Heidelberg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0315-8017","authenticated-orcid":false,"given":"Valentine","family":"Landrin","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/038t36y30","id-type":"ROR","asserted-by":"publisher"}],"name":"Heidelberg University 1 Heidelberg Myeloma Center, Department of Medicine V, University Hospital and Medical Faculty Heidelberg, , Heidelberg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4808-7857","authenticated-orcid":false,"given":"Niklas","family":"Kehl","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/038t36y30","id-type":"ROR","asserted-by":"publisher"}],"name":"Heidelberg University 1 Heidelberg Myeloma Center, Department of Medicine V, University Hospital and Medical Faculty Heidelberg, , Heidelberg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6401-3623","authenticated-orcid":false,"given":"Mirco J.","family":"Friedrich","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/038t36y30","id-type":"ROR","asserted-by":"publisher"}],"name":"Heidelberg University 1 Heidelberg Myeloma Center, Department of Medicine V, University Hospital and Medical Faculty Heidelberg, , Heidelberg, Germany."},{"name":"7Broad Institute of MIT and Harvard, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5772-7700","authenticated-orcid":false,"given":"Xiang","family":"Zhou","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03pvr2g57","id-type":"ROR","asserted-by":"publisher"}],"name":"University Hospital of W\u00fcrzburg 3 Department of Internal Medicine II, , W\u00fcrzburg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3644-9187","authenticated-orcid":false,"given":"Maximilian","family":"Steinhardt","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03pvr2g57","id-type":"ROR","asserted-by":"publisher"}],"name":"University Hospital of W\u00fcrzburg 3 Department of Internal Medicine II, , W\u00fcrzburg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3411-6559","authenticated-orcid":false,"given":"Philipp","family":"Weis","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03pvr2g57","id-type":"ROR","asserted-by":"publisher"}],"name":"University Hospital of W\u00fcrzburg 3 Department of Internal Medicine II, , W\u00fcrzburg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7651-8080","authenticated-orcid":false,"given":"Julia","family":"Mersi","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03pvr2g57","id-type":"ROR","asserted-by":"publisher"}],"name":"University Hospital of W\u00fcrzburg 3 Department of Internal Medicine II, , W\u00fcrzburg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5340-1818","authenticated-orcid":false,"given":"Johannes","family":"Waldschmidt","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03pvr2g57","id-type":"ROR","asserted-by":"publisher"}],"name":"University Hospital of W\u00fcrzburg 3 Department of Internal Medicine II, , W\u00fcrzburg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5464-3234","authenticated-orcid":false,"given":"Niels","family":"Weinhold","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/038t36y30","id-type":"ROR","asserted-by":"publisher"}],"name":"Heidelberg University 1 Heidelberg Myeloma Center, Department of Medicine V, University Hospital and Medical Faculty Heidelberg, , Heidelberg, Germany."},{"id":[{"id":"https:\/\/ror.org\/04cdgtt98","id-type":"ROR","asserted-by":"publisher"}],"name":"German Cancer Research Center (DKFZ) 2 Clinical Cooperation Unit Molecular Hematology\/Oncology, , Heidelberg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7011-0286","authenticated-orcid":false,"given":"K. Martin","family":"Kort\u00fcm","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03pvr2g57","id-type":"ROR","asserted-by":"publisher"}],"name":"University Hospital of W\u00fcrzburg 3 Department of Internal Medicine II, , W\u00fcrzburg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7166-5232","authenticated-orcid":false,"given":"Carsten","family":"M\u00fcller-Tidow","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/038t36y30","id-type":"ROR","asserted-by":"publisher"}],"name":"Heidelberg University 1 Heidelberg Myeloma Center, Department of Medicine V, University Hospital and Medical Faculty Heidelberg, , Heidelberg, Germany."},{"name":"8National Center for Tumor Diseases (NCT), Heidelberg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7680-0819","authenticated-orcid":false,"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03pvr2g57","id-type":"ROR","asserted-by":"publisher"}],"name":"University Hospital of W\u00fcrzburg 3 Department of Internal Medicine II, , W\u00fcrzburg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5552-3149","authenticated-orcid":false,"given":"Sandra","family":"Sauer","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/038t36y30","id-type":"ROR","asserted-by":"publisher"}],"name":"Heidelberg University 1 Heidelberg Myeloma Center, Department of Medicine V, University Hospital and Medical Faculty Heidelberg, , Heidelberg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9422-6614","authenticated-orcid":false,"given":"Katja","family":"Weisel","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01zgy1s35","id-type":"ROR","asserted-by":"publisher"}],"name":"University Medical Center Hamburg-Eppendorf 5 Department of Hematology, Oncology and Bone Marrow Transplantation With Section of Pneumology, , Hamburg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3588-6376","authenticated-orcid":false,"given":"Tim","family":"Richardson","sequence":"additional","affiliation":[{"name":"9Department of Internal Medicine I, University Hospital K\u00f6ln, K\u00f6ln, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9985-6583","authenticated-orcid":false,"given":"Raphael","family":"Teipel","sequence":"additional","affiliation":[{"name":"10Department of Internal Medicine, University Hospital Carl Gustav Carus Dresden, Dresden, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9536-9649","authenticated-orcid":false,"given":"Leo","family":"Rasche","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03pvr2g57","id-type":"ROR","asserted-by":"publisher"}],"name":"University Hospital of W\u00fcrzburg 3 Department of Internal Medicine II, , W\u00fcrzburg, Germany."},{"name":"11Mildred Scheel Early Career Center, W\u00fcrzburg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4181-6922","authenticated-orcid":false,"given":"Marc S.","family":"Raab","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/038t36y30","id-type":"ROR","asserted-by":"publisher"}],"name":"Heidelberg University 1 Heidelberg Myeloma Center, Department of Medicine V, University Hospital and Medical Faculty Heidelberg, , Heidelberg, Germany."},{"id":[{"id":"https:\/\/ror.org\/04cdgtt98","id-type":"ROR","asserted-by":"publisher"}],"name":"German Cancer Research Center (DKFZ) 2 Clinical Cooperation Unit Molecular Hematology\/Oncology, , Heidelberg, Germany."},{"name":"8National Center for Tumor Diseases (NCT), Heidelberg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"key":"2026050503070291500_bib1","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"2026050503070291500_bib2","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"key":"2026050503070291500_bib3","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1038\/s41591-023-02589-w","article-title":"Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial","volume":"29","author":"Bahlis","year":"2023","journal-title":"Nat Med"},{"key":"2026050503070291500_bib4","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41375-024-02154-5","article-title":"Real-world analysis of teclistamab in 123 RRMM patients from Germany","volume":"38","author":"Riedhammer","year":"2024","journal-title":"Leukemia"},{"key":"2026050503070291500_bib5","doi-asserted-by":"crossref","first-page":"e70114","DOI":"10.1002\/hem3.70114","article-title":"A German multicenter real-world analysis of talquetamab in 138 patients with relapsed\/refractory multiple myeloma","volume":"9","author":"Frenking","year":"2025","journal-title":"Hemasphere"},{"key":"2026050503070291500_bib6","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.2020010543","article-title":"CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed\/refractory large B-cell lymphoma","volume":"138","author":"Rejeski","year":"2021","journal-title":"Blood"},{"key":"2026050503070291500_bib7","doi-asserted-by":"crossref","first-page":"e004475","DOI":"10.1136\/jitc-2021-004475","article-title":"The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R\/R LBCL","volume":"10","author":"Rejeski","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026050503070291500_bib8","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1002\/ajh.27056","article-title":"The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL","volume":"98","author":"Rejeski","year":"2023","journal-title":"Am J Hematol"},{"key":"2026050503070291500_bib9","doi-asserted-by":"crossref","first-page":"5641","DOI":"10.1182\/bloodadvances.2025016689","article-title":"Population-based validation of the CAR-HEMATOTOX for hematotoxicity, infections, and survival after CART in R\/R LBCL","volume":"9","author":"de Boer","year":"2025","journal-title":"Blood Adv"},{"key":"2026050503070291500_bib10","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13045-023-01465-x","article-title":"The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed\/refractory multiple myeloma","volume":"16","author":"Rejeski","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"Supplement 1","key":"2026050503070291500_bib11","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1182\/blood-2024-208376","article-title":"Pre-apheresis prediction of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed\/refractory multiple myeloma","volume":"144","author":"Rejeski","year":"2024","journal-title":"Blood"},{"key":"2026050503070291500_bib12","doi-asserted-by":"crossref","first-page":"e414","DOI":"10.1016\/S2352-3026(17)30108-4","article-title":"EASIX in patients with acute graft-versus-host disease: a retrospective cohort analysis","volume":"4","author":"Luft","year":"2017","journal-title":"Lancet Haematol"},{"key":"2026050503070291500_bib13","doi-asserted-by":"crossref","first-page":"877477","DOI":"10.3389\/fimmu.2022.877477","article-title":"EASIX and severe endothelial complications after CD19-directed CAR-T cell therapy-a cohort study","volume":"13","author":"Korell","year":"2022","journal-title":"Front Immunol"},{"key":"2026050503070291500_bib14","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1182\/bloodadvances.2021004575","article-title":"CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity","volume":"5","author":"Greenbaum","year":"2021","journal-title":"Blood Adv"},{"key":"2026050503070291500_bib15","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1182\/bloodadvances.2020003885","article-title":"Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells","volume":"5","author":"Pennisi","year":"2021","journal-title":"Blood Adv"},{"key":"2026050503070291500_bib16","doi-asserted-by":"crossref","first-page":"e009220","DOI":"10.1136\/jitc-2024-009220","article-title":"EASIX-guided risk stratification for complications and outcome after CAR T-cell therapy with ide-cel in relapsed\/refractory multiple myeloma","volume":"12","author":"Frenking","year":"2024","journal-title":"J Immunother Cancer"},{"key":"2026050503070291500_bib17","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41408-023-00879-7","article-title":"Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel","volume":"13","author":"Raje","year":"2023","journal-title":"Blood Cancer J"},{"key":"2026050503070291500_bib18","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/cncr.35107","article-title":"Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed\/refractory multiple myeloma in the MajesTEC-1 study","volume":"130","author":"Nooka","year":"2024","journal-title":"Cancer"},{"key":"2026050503070291500_bib19","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1016\/S1470-2045(23)00159-6","article-title":"Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network","volume":"24","author":"Ludwig","year":"2023","journal-title":"Lancet Oncol"},{"key":"2026050503070291500_bib20","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1016\/S1470-2045(24)00043-3","article-title":"International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma","volume":"25","author":"Rodriguez-Otero","year":"2024","journal-title":"Lancet Oncol"},{"key":"2026050503070291500_bib21","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41408-025-01282-0","article-title":"Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma","volume":"15","author":"Mohan","year":"2025","journal-title":"Blood Cancer J"},{"key":"2026050503070291500_bib22","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.cmi.2024.02.023","article-title":"Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: a national retrospective study","volume":"30","author":"Jourdes","year":"2024","journal-title":"Clin Microbiol Infect"},{"key":"2026050503070291500_bib23","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41408-025-01259-z","article-title":"Real-world evaluation of teclistamab for the treatment of relapsed\/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study","volume":"15","author":"Tan","year":"2025","journal-title":"Blood Cancer J"},{"key":"2026050503070291500_bib24","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1111\/bjh.19700","article-title":"Immune prognostic score predicts the risk of infection and survival outcomes in patients with relapsed multiple myeloma treated with bispecific antibodies","volume":"205","author":"Akhtar","year":"2024","journal-title":"Br J Haematol"},{"key":"2026050503070291500_bib25","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N Engl J Med"},{"key":"2026050503070291500_bib26","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026050503070291500_bib27","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol"},{"key":"2026050503070291500_bib28","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/bloodadvances.2018019034","article-title":"Exposure-adjusted adverse events comparing blinatumomab with chemotherapy in advanced acute lymphoblastic leukemia","volume":"2","author":"Stein","year":"2018","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"2026050503070291500_bib29","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1182\/blood-2023-191305","article-title":"Pooled analysis on bispecific antibody-related toxicities in multiple myeloma","volume":"142","author":"Golmohammadi","year":"2023","journal-title":"Blood"},{"key":"2026050503070291500_bib30","doi-asserted-by":"crossref","first-page":"5479","DOI":"10.1182\/bloodadvances.2023012522","article-title":"Molecular mechanisms promoting long-term cytopenia after BCMA CAR-T therapy in multiple myeloma","volume":"8","author":"Palacios-Berraquero","year":"2024","journal-title":"Blood Adv"},{"key":"2026050503070291500_bib31","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1182\/bloodadvances.2019000600","article-title":"T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma","volume":"3","author":"Garfall","year":"2019","journal-title":"Blood Adv"},{"key":"2026050503070291500_bib32","doi-asserted-by":"crossref","first-page":"E386","DOI":"10.1002\/ajh.26293","article-title":"Lines of therapy before autologous stem cell transplant and CAR-T affect outcomes in aggressive Non-Hodgkin\u2019s lymphoma","volume":"96","author":"Khurana","year":"2021","journal-title":"Am J Hematol"},{"issue":"Supplement 1","key":"2026050503070291500_bib33","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2020-134369","article-title":"Effects of prior alkylating therapies on preinfusion patient characteristics and starting material for CAR T cell product manufacturing in late-line multiple myeloma","volume":"136","author":"Rytlewski","year":"2020","journal-title":"Blood"},{"issue":"Supplement 1","key":"2026050503070291500_bib34","doi-asserted-by":"crossref","first-page":"10402","DOI":"10.1182\/blood-2022-167804","article-title":"High metabolic tumor volume is associated with higher toxicity and decreased efficacy of BCMA CAR-T cell therapy in multiple myeloma","volume":"140","author":"Villanueva","year":"2022","journal-title":"Blood"},{"key":"2026050503070291500_bib35","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1200\/JCO.22.01365","article-title":"Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the myeloma CAR T consortium","volume":"41","author":"Hansen","year":"2023","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"2026050503070291500_bib36","doi-asserted-by":"crossref","first-page":"12778","DOI":"10.1182\/blood-2022-158080","article-title":"Baseline systemic inflammatory markers interleukin 6 and ferritin are associated with toxicities and progression-free survival in multiple myeloma patients treated with idecabtagene vicleucel","volume":"140","author":"Hansen","year":"2022","journal-title":"Blood"},{"key":"2026050503070291500_bib37","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"2026050503070291500_bib38","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: a report from International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"key":"2026050503070291500_bib39","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1182\/blood-2015-05-647636","article-title":"Guidelines for determination of the number of prior lines of therapy in multiple myeloma","volume":"126","author":"Rajkumar","year":"2015","journal-title":"Blood"},{"key":"2026050503070291500_bib40","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"key":"2026050503070291500_bib41","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/s41408-021-00527-y","article-title":"Extramedullary disease in multiple myeloma","volume":"11","author":"Bansal","year":"2021","journal-title":"Blood Cancer J"},{"key":"2026050503070291500_bib42","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41408-021-00474-8","article-title":"Chromosome 1q21 abnormalities in multiple myeloma","volume":"11","author":"Schmidt","year":"2021","journal-title":"Blood Cancer J"},{"key":"2026050503070291500_bib43","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"key":"2026050503070291500_bib44","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood"},{"key":"2026050503070291500_bib45","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.bbmt.2015.09.013","article-title":"Infections after transplantation of bone marrow or peripheral blood stem cells from unrelated donors","volume":"22","author":"Young","year":"2016","journal-title":"Biol Blood Marrow Transpl"},{"key":"2026050503070291500_bib46","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1182\/bloodadvances.2024012724","article-title":"Patterns of CRS with teclistamab in relapsed\/refractory multiple myeloma with or without prior T-cell redirection therapy","volume":"8","author":"Hamadeh","year":"2024","journal-title":"Blood Adv"},{"key":"2026050503070291500_bib47","doi-asserted-by":"crossref","first-page":"181","DOI":"10.5772\/intechopen.81683","article-title":"Infections in patients with multiple myeloma in the era of novel agents and stem cell therapies","volume-title":"Update on multiple myeloma","author":"Al-Jasser","year":"2019"},{"key":"2026050503070291500_bib48","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"}],"container-title":["Blood Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-25-0062\/3737908\/bcd-25-0062.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-25-0062\/3767737\/bcd-25-0062.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/7\/3\/479\/3783152\/bcd-25-0062.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/7\/3\/479\/3783152\/bcd-25-0062.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T07:07:13Z","timestamp":1777964833000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article\/7\/3\/479\/784446\/Clinical-Scores-to-Predict-Toxicities-and-Outcomes"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":48,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,2,13]]},"published-print":{"date-parts":[[2026,5,5]]}},"URL":"https:\/\/doi.org\/10.1158\/2643-3230.bcd-25-0062","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2643-3230.32697018","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.32697072","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.32697060","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.32697084","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.32697030","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.32697042","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.32697054","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.32697078","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.32697066","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.32697024","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.32697048","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.32697039","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.32697081","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.32697051","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.32697063","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.32697075","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.32697021","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.32697033","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.32697045","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.32697069","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.32697057","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.32697015","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.32697027","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2643-3230.c.8541894","asserted-by":"object"}]},"ISSN":["2643-3230","2643-3249"],"issn-type":[{"value":"2643-3230","type":"print"},{"value":"2643-3249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,13]]}}}